

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 30 November 2022 (the “**Prospectus**”) issued by Meihao Medical Group Co., Ltd (美皓醫療集團有限公司) (the “**Company**”).*

*This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purpose only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any security. This announcement is not a prospectus. Potential investors should read the Prospectus carefully for detailed information about the Company and the Global Offering.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. There will be no public offering of securities of the Company in the United States.*



**Meihao Medical Group Co., Ltd**

**美皓醫療集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1947)**

## **END OF STABILISATION PERIOD, STABILISING ACTIONS AND LAPSE OF OVER-ALLOTMENT OPTION**

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

### **END OF STABILISATION PERIOD**

The Company announces that the stabilisation period in connection with the Global Offering ended on Thursday, 5 January 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

### **NO STABILISING ACTION AND LAPSE OF OVER-ALLOTMENT OPTION**

As there was no over-allocation of the International Placing Shares in the International Placing, the Overall Coordinator (for itself and on behalf of the International Underwriters) did not exercise the Over-allotment Option and no stabilising actions were undertaken by the Stabilising Manager, its affiliates or any person acting for it during the stabilisation period.

The Over-allotment Option lapsed on Thursday, 5 January 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Accordingly, no Share was or will be issued under the Over-allotment Option.

## **PUBLIC FLOAT**

The Directors confirm that the Company continues and will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules whereby at least 25% of the Company's total number of issued Shares must at all times be held by the public.

By order of the Board  
**Meihao Medical Group Co., Ltd**  
**Mr. Wang Xiaomin**  
*Chairman and executive Director*

Hong Kong, 5 January 2023

*As at the date of this announcement, the executive Directors are Mr. Wang Xiaomin and Ms. Zheng Man, and the independent non-executive Directors are Mr. Ng Ming Chee, Ms. Tam Hon Shan Celia and Dr. Zhou Jian.*